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1. Introduction 
Alpha-1 antitrypsin (AT) is a member of the serine proteinase inhibitor (SERPIN) 
superfamily. It is an acute phase protein produced constitutively, primarily by hepatocytes, 
and is secreted in to the plasma from where it diffuses into the lung. AT is the most 
abundant proteinase inhibitor within the lung whose main physiological role is to regulate 
neutrophil elastase (NE) liberated from activated neutrophils (Brantly et al., 1988a; Lomas 
and Mahadeva, 2002).  
The importance of AT in pulmonary biology was demonstrated by the association between 
severe plasma deficiency and pulmonary emphysema (Laurell and Eriksson., 1963). These 
findings in conjunction with Gross et al., 1965 formed the basis of the proteinase-
antiproteinase hypothesis for the development of emphysema and other lung diseases. It 
was subsequently identified that the Z variant is the commonest cause of severe AT 
deficiency. It results in aggregation of the protein in the hepatocyte (with a predisposition to 
liver disease) resulting in a secretory defect and deficiency. Initially it was presumed that 
NE and AT were the most important proteinase and anti-proteinase respectively within the 
lung, but it is now appreciated that several proteinases and inhibitors exist within the lung 
and other mechanisms are important e.g. apoptosis, ageing, oxidants. Nevertheless, no other 
PI and proteinase have been so clearly linked with pulmonary emphysema, thus 
emphasizing the important role of AT in lung biology. Despite this long association, 
epidemiological studies suggest that AT deficiency is under-recognized or misdiagnosed 
(Bull World Health Organ, 1997; ATS-ERS statement, 2003). 
1.1 Nomenclature and detection of mutants 
The AT protein is an extremely polymorphic molecule; there are over 100 variants of AT 
resulting from mutations in the SERPINA1 gene. They are named by the letter of the 
alphabet according to the migration of the glycosylated form of the protein on isoelectric 
focusing (IEF). The wildtype protein is therefore termed M-AT as it is associated with 
normal level of serum AT and it has a medium rate of migration on IEF. Variants that 
migrate faster than M-AT are classified as A to L or slower than M-AT are classified as N to 
Z (A being the fastest and Z the slowest) (Brantly et al., 1988a; 1991; Cox et al., 1980; 
Fagerhol and Laurell, 1967). On the basis of their plasma level and function, the majority of 
individuals are M homozygotes (M1-5 subtypes). 
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1.2 Genotyping 
Currently, diagnosis of AT deficiency is based on the measurement of AT levels in the 
serum and/or phenotyping by IEF of the serum within a narrow pH range on the 
polyacrylamide gel. The latter has been standard practice for many years, but is time 
consuming, difficult to interpret and limited to a few reference laboratories. Genotyping by 
real-time PCR and Restriction Fragment-Length Polymorphism PCR (RFLP-PCR) are highly 
effective, relatively inexpensive and reliable, and as a consequence are now commonly 
performed. Direct sequencing of coding exons of the gene can also be used as an adjunct in 
selected cases to clarify genotyping (Zorzetto et al., 2008; Miravitlles et al., 2010). 
1.3 Alpha-1-antitrypsin gene expression 
The AT gene is located on chromosome 14q31-32.1, and is co-dominantly expressed 
(Schroeder et al., 1985; Bull World Health Organ, 1997; Brantly et al., 1988). The gene is 12 kb 
in length and contains seven exons (Ia, b c and II–V) and six introns. Exon I contains the 3’ 
untranslated promoter sequences: Ia and Ib contains the promoter sequence for 
macrophage-specific, and Ic for hepatocyte-specific transcription, respectively. The coding 
regions (Exons II-V) are 1434 base-pairs (bp) in length and the reactive centre is within Exon 
V (Long et al., 1984). Aside from the promoter elements, there are other regulatory 
sequences including an enhancer element in the 5' and 3' flanking sequences of exonic 
regions of the AT gene. A polymorphism in the 3’ flanking region is associated with 
susceptibility to COPD (Kalsheker et al., 1987; Morgan et al., 1992). A map of single 
nucleotide polymorphisms (SNPs) in the 5' and 3' flanking regions showed that among the 
15 SNPs, five SNPs increased the risk of COPD by 6- to 50-fold (Chappell et al., 2006). These 
polymorphisms within regulatory sequences are associated with normal basal plasma levels, 
but can result in reduced levels of AT transcription in response to stimulation in vitro, which 
is postulated to relate to the susceptibility to COPD (Henry et al., 2001; Chappell et al., 2006). 
However, this has not been proven in vivo (Mahadeva et al., 1998; de Faria et al., 2005; 
Courtney et al., 2006, Brennan, 2007). 
1.4 Variants associated with alpha-1 antitrypsin deficiency 
The commonest cause of severe deficiency in Caucasians is Z-AT (Glu342Lys). Four percent 
of North Europeans carry this variant, and amongst them 1/2000 are PiZ homozygotes 
(Fagerhol, 1974). The frequencies of PiZ are 1/2700 in USA and 1/5000 in UK (Cook, 1975; 
de Serres, 2002; Brantly et al., 1988a). The distribution of the genetic types (PI alleles) of AT 
has been investigated in many populations. Some variants are only common in specific 
populations; the Z mutant is rare in Asian and African populations, whereas the S (364 Glu-
Val) variant is more frequent in the Mediterranean area. The plasma level of the principal 
AT phenotypes are MM (20-39 µmol/L), MS (19-35 µmol/L), SS (14-20 µmol/L), MZ (13-23 
µmol/L), SZ (9-15 µmol/L), ZZ (2-8 µmol/L). About 20 variants are associated with lower 
but detectable AT in plasma (Table 1). The dysfunctional Pittsburgh (M358R) variant 
converts AT from an elastase inhibitor to a thrombin inhibitor due to mutation in the active 
site. The Null (QO) variants occur as a result of insertion or deletion of nucleotides. They are 
associated with only trace amounts (less than 1%) of AT in plasma and associated with 
increased risk for emphysema (Bull Health World Organ, 1997; ATS-ERS, 2003). 
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 Variants Mutations Mechanism of deficiency Clinical 
disease 
References 
Severe      
 Z (E342K) polymerization in liver 
cells; reduced inhibitory 
activity; deficiency 
Emphysema
Liver disease
Oakeshott et 
al., 1985; 
Carell, 1990; 
Ogushi et al., 
1987 
 Siiyama (F53S) polymerization in liver cells 
and plasma; deficiency 
Emphysema
Liver disease
Seyama et al., 
1991 
 Mmalton (52Phe 
deleted) 
polymerization in liver 
cells; deficiency 
Emphysema
Liver disease
Cox and 
Billingsley, 
1989;Roberts 
et al., 1984 
 Mheerlen (P369L) intracellular degradation; 
deficiency 
Emphysema Kramps et al., 
1981 
 Mprocida (L41P) decreased inhibitory 
activity; deficiency 
Emphysema Takahashi et 
al., 1988; 
Holmes et al., 
1990 (a) 
 P (D256V) intracellular degradation; 
deficiency 
Emphysema Holmes et al., 
1990 (b) 
 Pittsburgh (M358R) altered substrate specificity Serous 
bleeding 
Owen et al., 
1983 
Mild      
 S (E264V) incorrect splicing of mRNA; 
abnormal intracellular 
degradation; 
polymerization in liver cells
 Elliott et al., 
1996a; 
Schindler, 
1984; Engh et 
al., 1989 
 I (R39C) polymerization; slightly 
decreased inhibitory 
activity; mild deficiency 
Emphysema Mahadeva et 
al., 1999; 
Graham et al., 
1989; Baur and 
Bencze, 1987 
 Mmineral 
Springs 
(G67E) aberrant posttranslational 
biosynthesis; loss of 
conserved Gly; disturbed 
packing; degraded in liver 
cells; decreased inhibitory 
activity; deficiency 
Emphysema Curiel et al., 
1990 
 F (R223C) polymerization; decreased 
inhibitory activity 
 Okayama et 
al., 1991; 
Hayes et al., 
1992 
Table 1. Alpha-1-antitrypsin variants associated with plasma deficiency 
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1.5 Molecular structure of α1-antitrypsin 
AT consists of three β-sheets, eight ǂ-helices, and a reactive centre loop (RCL), which 
contains the residues that directly interact with the proteinase substrate (Fig. 1). ǃ-Sheet A is 
composed of five strands spreading along the long axis of the protein: the first strand has 5-6 
residues and the other strands have 12-15 residues. In the native conformation, the 17 amino 
acid RCL locates at an external position in relation to the body of the molecule between the 
C-terminus of ǃ-sheet A3 and the N-terminus of ǃ-sheet C1. The N-terminal side of the 
reactive loop including M358 (P1) is directly related to the recognition and binding of the 
substrate (Fig. 1) (Song et al., 1995; Silverman et al., 2001; Elliott et al., 1996a; Ryu et al., 1996; 
Kim et al., 2001) 
 
Pathways of polymerization of ǂ1-antitrypsin. The structure of ǂ1-antitrypsin is centred on ǃ-sheet A 
and the mobile RCL. Polymer formation results from the Z-AT (E342K at P17; Z) or other mutations in 
the shutter domain, which open ǃ-sheet A to favour partial loop insertion and the formation of an 
unstable intermediate (M*). The patent ǃ-sheet A can accept either the loop of another molecule, to form 
a dimer (D), which then extends into polymers (P), or else its own loop, to form a latent conformation 
(L). The individual molecules of AT within the polymer are shown in different shades of grey. 
Reproduced from Lomas and Mahadeva, 2002. 
Fig. 1. Mechanism of Z ǂ1-antitrypsin polymerization  
1.6 Physiology and function of α1-antitrypsin 
AT is a 394 amino acid (52 KDa) glycoprotein produced primarily by hepatocytes. Other 
cells produce the protein to a lesser extent in peripheral blood monocytes, alveolar 
macrophages and bronchial epithelial cells and gastrointestinal mucosa. (Brantly et al., 
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1988a; Cichy et al., 1997). Daily production of AT is 34 mg/kg. The large amount of AT in 
the circulation and lung is primarily present to control the activity of elastase in the lung. 
NE is the main substrate for AT, accordingly it inhibits 90% of the NE in circulation and 
interstitium of lung. AT also inhibits the serine proteinases cathepsin G and proteinase 3.  
1.7 Other biological effects of alpha-antitrypsin 
In addition to acting as an antiproteinase, AT plays important role in modulating 
inflammation. It may inhibit immune responses, and fibroblast-proliferation and fibroblast 
procollagen production thereby contributing to repair and matrix production (Dabbagh et 
al., 2001), and have antibacterial activities (Hadzic et al., 2006), and also blocks the cytotoxic 
and stimulatory activity of defensins (Hiemstra et al., 1998). AT also has direct and indirect 
anti-apoptotic properties by inhibiting caspase-3 or NE mediated apoptosis, respectively 
(Petrache et al., 2006). AT is also involved in calcium-induced activation mechanisms; AT 
inactivates calpain I (μ-calpain), induces a rapid cell polarization and random migration of 
neutrophils The role of AT in neutrophil regulation was further supported by its ability to 
transiently increase calcium from intracellular stores, which is linked to neutrophil 
polarization. AT modulated increase in intracellular lipids, activation of the Rho GTPases, 
Rac1 and Cdc42, and extracellular signal-regulated kinase (ERK1/2) all these kinases are 
indeed found to be activated or phosphoryated in polarized neutrophils with significant 
mobility (Al-Omari et al., 2011). Furthermore, a recent study demonstrated that AT can 
control immune complex–mediated neutrophil chemotaxis by inhibiting ADAM-17 (TACE) 
activity and preventing the release of glycosylphosphatidylinositol-linked (GPI-linked) 
membrane protein, FcǄRIIIb, from the cell (Bergin et al., 2010). The same study also 
demonstrated in vivo, that AT is a potent inhibitor of neutrophil chemotaxis in Z-AT 
individuals compared with M-AT individuals correlating with increased chemotactic 
responses of both CXCR1 and immune complex receptor (FcǄRIIIb) (Bergin et al., 2010).  
1.8 Mechanism of proteinase inhibition 
The process of inhibition is initiated by the specific binding of the proteinase to the RCL of 
AT to form a non-covalent Michaelis complex and is one of “suicide substrate inhibition” 
(Gettins, 2002). The inhibitory mechanism of AT relies upon cleavage of the methionine-
serine P1-P1’ by NE (1:1 AT-elastase complex). The protease is then swung 70 Å (1 Å = 0.1 
nm) from the upper pole to the lower pole of the protein in association with the insertion of 
the reactive loop as an extra strand into ǃ-sheet A. The complex inactivates the protease by 
distortion of the catalytic triad at the active site (Huntington et al., 2000; Wilczynska et al., 
1997; Stratikos and Gettins, 1997). The stable complex is subsequently recognized and 
cleared by the liver. The complexes are short lived (a few hours) in the circulation compared 
with the native AT (5-6 days), and the low-density lipoprotein receptor related protein 
(LRP) on liver cells appears to be the principal receptor for clearance of the AT-proteinase 
complexes (Kounnas et al., 1996).  
1.9 Mutations and their effect on conformation of AT 
Molecular mobility and the P1 methionine is essential for elastase inhibitory behaviour, but 
is also its Achilles heel making the molecule vulnerable to the effects of critically situated 
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point mutations and oxidation (Stein and Carrell, 1995). AT molecules can undergo 
conformational transitions, which not only inactivate is antiproteinase function, but also 
confers it with other biological properties.  
2 Conformations and their effect on structure and function of α1-antirypsin 
2.1 Conformations of α1-antirypsin 
In vivo AT can exist in different conformational forms; native, oxidized, polymerized, 
oxidized-polymers, RCL cleaved and latent, and the AT-elastase complex. The 
conformational changes can be the result of inflammation, such as the cleavage by non-
target proteinases and oxidation by reactive oxygen species (ROS). Mutaations e.g Z, S 
predispose it to polymerization. Whilst these conformations result in a loss of proteinase 
inhibitory activity, they can have biological effects such as inflammatory cell activation and 
chemotaxis, cytokine release or apoptosis (Janciauskiene, 2001). 
2.2 Oxidized AT 
Oxidation of AT is a sulphoxide modification of the methionine residues of AT (Johnson and 
Travis, 1979; Beatty et al., 1980; Taggart et al., 2000). Methionine can be attacked by various 
oxidants, such as peroxide, hydroxyl radicals, hypochloride, chloramines and peroxynitrite 
(Vogt, 1995; Rahman and MacNee, 1996), which are mainly produced by activated 
inflammatory cells. Oxidized AT (Ox-AT) in vivo has been confirmed by the finding that the 
inactive AT purified from the inflammatory synovial fluid contains methionine sulphoxide 
residues, and that 41% of total AT in the fluid is inactive, oxidized and/or cleaved (Zhang et 
al., 1993). Smoking is a major external source of oxidants (Rahman and MacNee, 1996; Church 
and Pryor, 1985; Schaberg et al., 1992). In smoking-related emphysema, 5-10% of total AT is in 
the oxidized state (Wong and Travis, 1980). Oxidation of the P1 methionine (M358) 
significantly reduces the activity of AT against NE to 1/2000 of the normal (Johnson and 
Travis, 1979). Recent data demonstrates that oxidation of Z-AT promotes polymerization of Z-
AT thus increasing the risk of emphysema of Z-AT deficient patients (Alam et al., 2011). Ox-
AT has also been shown to stimulate release of MCP-1 and IL-8 from lung epithelial cells (Li et 
al., 2009) and stimulate monocyte activation, inducing an elevation in MCP-1, IL-6, TNF-ǂ 
expression and NADPH oxidase activity (Moraga and Janciauskiene., 2004) 
2.3 Polymerized form 
The Z-variant accumulates in the hepatocyte involving a process of loop-sheet 
polymerization whereby the RCL of one molecule inserts into ǃ-sheet A of a second and so 
on to form chains of Z-AT polymers (Lomas et al., 1992; Mahadeva et al., 1999). M-AT has 
not been found to polymerize in vivo (Mahadeva et al., 2005). Polymerization can occur in 
other variants of AT, such as Siiyama, Mmalton, I, and S (Mahadeva et al., 1999; 
Janciauskiene et al., 2004; Elliott et al., 199b). I ǂ1-antitrypsin and S-AT polymerize slower 
than Z-AT but faster than M-AT, and hence are associated with less severe plasma 
deficiency (Dafforn et al.,1999).  
The occurrence of Z-AT polymerization in vivo has been confirmed by the finding of AT 
polymers in lungs (Elliot et al., 1998b; Mulgrew et al., 2004). Polymers of Z-AT are found in 
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emphysematous alveolar walls (Mahadeva et al., 2005). Polymers of Z-AT are chemotactic for 
neutrophils (Parmar et al., 2002; Mulgrew et al., 2004). Polymers of Z-AT are also ineffective 
anti-inflammatory molecules or inhibitors of NE, (Alam et al., 2011; Bergin et al., 2010; Al-
Omari et al., 2011). Recent findings show that ER accumulation of Z-AT polymers is associated 
with up-regulation of PKR-like ER kinase (PERK), regulator of G-protein signaling (RGS) 16, 
and calnexin, and NF-B activation and secretion of inflammatory mediators; IL-6 and IL-8 in 
keeping with activation of the ER overload response (EOR) linked to excess inflammatory 
activity of the Z-AT cell (Alam et al., Unpublished observation). 
3. Mechanisms of disease and pathology 
3.1 Alpha-1-antitrypsin associated diseases  
The normal plasma concentration of AT is about 30 μM, providing 24 μM in lung 
interstitium, which is thought to be critical in inhibiting elastase. It has been calculated that a 
concentration of 11 μM of plasma AT is the threshold for providing sufficient AT in the lung 
(Wewers et al., 1987; Stockely, 2003). Hence, although some phenotypes of AT are associated 
with abnormally low concentrations of AT in the plasma; PiMS: 80% of normal, PiSS: 60%; 
PiMZ: 57.5%, only PiSZ, 40%, and PiZ:10-15% and Null variants have been linked to the 
development of lung disease (Brantly et al., 1988a;b). AT deficiency appears to be under-
diagnosed in some populations (Bull World Health Organ, 1997; de Serres, 2003) with only a 
small proportion of those predicted according to allele frequencies to have AT deficiency to 
have been identified: 4.5% in UK, 6% in Sweden, and 5% in USA (Tobin et al., 1983; Larsson, 
1978; Silverman et al., 1989). 
3.2 Z α1-antitrypsin associated lung disease 
Cigarette smoking is the most important independent risk factor for the development of 
emphysema in the Western world. A landmark study (Fletcher et al., 1977) showed that 15 
to 25% of smokers with normal AT develop clinically significant COPD, and that the rate of 
FEV1 (forced expiratory volume in 1 second) decline was around 50 ml/year in smokers 
compared with 25 ml/year in non-smokers. Among the AT-deficient population, the decline 
of FEV1 is 70 ml/year in current smokers compared with 41 ml/year in ex-smokers 
(Piitulainen and Eriksson, 1999). Smokers with severe deficiency of AT develop symptoms 
of emphysema 10-15 years earlier than those non-smoking individuals and have a higher 
mortality (Buist et al., 1983; Janus et al., 1985).  
Severe AT deficiency usually due to Z-AT accounts for about 2% of cases of emphysema 
(Morse, 1978), and has also been linked to asthma and bronchiectasis (Parr et al., 2007; 
Eden et al., 1997; King et al., 1996; Bleumink and Klokke, 1985). Individuals, who have 
never smoked, rarely develop symptoms before the age of 50. Twenty-40% of patients 
have chronic bronchitis and bronchiectasis, and about half have exacerbations (Needham 
and Stockley, 2004). Most PiZ non-index cases have normal or slightly abnormal lung 
function in the absence of symptoms (Tobin et al., 1983). The development of lung disease 
is intimately related to cigarette smoking. However, the severity of lung disease can show 
some variability: lung function is well maintained in some AT-deficient smokers, while 
can be impaired in non-smokers (Brantly et al., 1988b; Janus et al., 1985). It is also 
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postulated that host factors, such as individual bronchodilator reversibility, baseline lung 
function, sex, age, and other unidentified genetic factors as well as other environmental 
factor such as dust-exposure and recurrent respiratory infections may influence the 
clinical phenotype (Needham and Stockley, 2004). A recent familial study estimated 
heritability for FEV1/forced vital capacity (FVC) in 378 ZZ homozygotes from 167 families 
identified cigarette smoking as the genetic modifier in the pathogenesis and severity of 
COPD (DeMeo et al., 2009). 
3.3 MZ α1-antitrypsin associated lung disease 
The serum levels of AT in MZ heterozygotes is lower than in MM homozygotes (Section 
1.4), but whether MZ individuals have an increased risk of COPD remains controversial. 
Increased COPD risk in this group may have public health implications because there are 
about 117 million of MZ and MS phenotypes worldwide (de Serres 2002; Brantly et al., 
1991). Many studies have addressed the risk of lung function reduction and increased risk 
of COPD in MZ heterozygotes, but the results have not been consistent. A meta-analysis 
demonstrated increased risk of COPD in MZ compared to MM, but there was no 
difference in mean FEV1 between MZ and MM individuals when combining the results 
from population-based studies (Hersh et al., 2004), which is in agreement with a cohort of 
MZ heterozygotes analyzed from the Danish Alpha-1-Antitrypsin Deficiency Registry 
(Seersholm et al., 2000) and a longitudinal study of the general population in Arizona 
(Silva et al., 2003). Many of the previous studies have been limited by small sample sizes, 
varying phenotype definitions, or failure to adjust for smoking. However, recent studies 
investigated two large, well characterized populations of current and ex-smokers, a case-
control study and a multicenter family-based study using quantitative CT scan 
measurements of emphysema and airway disease, established an association of reduced 
FEV1/FVC in MZ compared to MM (Sandhaus et al., 2008; Sørheim et al., 2010). This 
suggests that at least some MZ heterozygotes are more susceptible to the development of 
COPD. Interestingly, MZ with a low smoking history (<20 pack-year) had more severe 
emphysema on chest CT scan. It remains to be established whether all MZ individuals 
have an increased risk or whether a subset is more susceptible because of other genetic or 
environmental factors.  
3.4 Mechanism of Z α1-antitrypsin-related emphysema 
The majority of emphysema occurs in cigarette smokers who have normal AT 
concentrations and smoking can injure the lungs by many mechanisms, such as, A. 
increasing the oxidant burden (Alam et al., 2011; Church and Pryor, 1985; Carp and Janoff, 
1978); B. direct stimulation of neutrophils and macrophages to produce proteinases 
(Bracke et al., 2005; Hautamaki et al., 1997); C. inactivation of AT and other proteinase 
inhibitors by oxidation (Alam et al., 2011; Wong and Travis, 1980); D. interfering the 
repairing process by repeated damage (Janoff et al., 1983). These mechanisms can all occur 
in Z-AT individuals. However, there are some noteable differences in emphysema due to 
Z-AT compared to those with normal AT. Firstly, the emphysema has a predilection 
(although not exclusively) at least initially to affect the lower lobes in Z-AT emphysema 
compared with the upper lobes in M-AT emphysema. Secondly, the emphysema in Z-AT 
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individuals tends to have more polymorpholeucocytes compared with M-AT emphysema 
(Morrison et al., 1987). 
The main mechanism contributing to the development of emphysema in individuals with Z-
AT is the imbalance of AT-elastase, in favour of elastase caused by severe AT deficiency. It is 
now well established that the conformational changes originating from this mutation 
predispose Z-AT molecules to irreversible polymerization, with consequent accumulation 
within the ER of hepatocytes (Lomas et al., 1992; Mahadeva et al., 2002). As a consequence, 
only approximately 15% of the molecules produced reach the circulation. In addition, in the 
presence of cigarette smoking a major portion of these secreted proteins has been shown to 
be either oxidized monomeric AT or in its polymeric form (Alam et al., 2011), which are 
inactive as proteinase inhibitors. Z-AT also has a reduced activity against elastase 
(Oakeshhott et al., 1985; Lomas et al., 2003). The inactivation of AT as in M-AT related 
emphysema can also occur by cleavage by non-target proteinases. The end result of these 
processes is a further reduction in the quantity of functional AT. 
Polymeric conformation of Z-AT has also been found in Z-AT emphysematous lungs in 
association with neutrophils (Mahadeva et al., 2005). Polymers of Z-AT are also thought to 
contribute the inflammation and lung damage in emphysema. Polymers of Z-AT are 
thought to be produced locally within the lung, however, a recent study reported finding of 
polymers of Z-AT not only in the lung, but also in the serum of transgenic mice expressing 
human Z-AT that had been exposed to cigarette smoke (Alam et al., 2011) (Section 3.4). 
Formation of Z-AT polymers may be accelerated by local inflammation e.g. bacterial 
infection. The polymers are themselves chemotactic for human neutrophils in vitro and in 
vivo and are co-localized with neutrophils in the alveoli of individuals with Z-AT-related 
emphysema (Elliott et al., 1998a; Parmar et al., 2002; Mulgrew et al., 2004). The transition of 
native Z-AT to polymers inactivates its anti-proteinase and anti-inflammatory function, and 
also converts it to a pro-inflammatory stimulus and may explain the excess numbers of 
neutrophils in bronchoalveolar lavage fluid (BALF) and lung tissue from Z-AT 
homozygotes (Morrison et al., 1987; Mahadeva et al., 2005) and in transgenic Z-AT mice 
(Alam et al., 2011). The presence of polymers may also contribute to the progression of PiZ 
lung disease after smoking cessation.  
3.5 Cigarette smoking and emphysema 
Z-AT related emphysema is potentiated by cigarette smoking, characteristically occurring in 
the third to fourth decade compared with fifth to sixth decade in non-smokers (Luisetti and 
Seersholme, 2004; Evald et al., 1990). The mechanism of accelerated decline in smokers with 
Z-AT is in part due to the independent effects of cigarette smoke, but also due to oxidation 
of Z-AT which promotes polymerization (production of oxidized polymers) of Z-AT (Fig. 2) 
(Alam et al., 2011). Polymers are inactive as an anti-elastase, and are not only unable to 
perform their normal anti-inflammatory role, but are also chemotactic for neutrophils (Alam 
et al., 2011; Mulgrew et al., 2004; Morrison et al., 1987; Parmar et al., 2002; Bergin et al., 2010; 
Al-Omari et al., 2011). The acceleration of COPD by cigarette smoke in Z-AT individuals 
exemplifies the critical importance of gene-environmental interactions to the development 
of COPD. This provides a molecular explanation for the striking association of premature 
emphysema in ZZ homozygotes who smoke. 
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Proposed model for the pathogenesis of emphysema in patients with Z-AT deficiency. Cigarette smoke 
induces oxidation of Z-AT, which accelerates Z-AT polymerization. Plasma deficiency and reduced 
inhibitory activity of Z-AT would be exacerbated by the oxidation and polymerization of AT within the 
lungs, thereby further reducing the antiproteinase screen. Conversion from a monomer to a polymer 
results in a loss of anti-inflammatory effect. Z-AT polymers also act as a pro-inflammatory stimulus to 
attract and activate neutrophils, resulting in further increase in neutrophils and liberation of NE thereby 
imbalance of AT-elastase in the favour of NE leading to tissue damage and subsequently causing 
emphysema. Adapted from Alam et al., 2011. 
Fig. 2. Schematic diagram depicting the role of conformations of ǂ1-antitrypsin and the 
interaction with cigarette smoke in the development of emphysema. 
4. Prognosis and review of current treatments  
4.1 Treatment of Z α1-antitrypsin-associated lung disease 
The major goals in the management of patients with Z-AT related emphysema are to 
prevent lung disease, and to reduce progression of the disease. Smoking cessation and 
standard management for COPD with normal AT levels is of crucial importance once the 
diagnosis has been made. Repeated respiratory infections can lead to permanent lung injury 
in patients with Z-AT deficiency. Thus, reducing exacerbation rate is also essential. 
Purified plasma AT (half-life of 4.5 day) and recombinant AT (half-life of a few hours) are 
both commercially available. Currently four different preparations of purified plasma AT 
are available worldwide; Prolastin®, ZemairaTM, AralastTM and Trypsone® and have been 
approved for use by the regulatory agencies in several countries (Table 2). The former three 
preparations are available in the United States at an estimated cost of $60,000 to $150,000 per 
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year (Gildea et al., 2003). There is no definitive evidence to suggest superiority (specific 
functional inhibitor activity) of any one of the formulation comparing them to Prolastin. 
Prolastin was the first approved human purified plasma AT, which is usually administrated 
intravenously at 60 mg/kg weekly. This dose increased the serum AT level and remained 
above the putative protective threshold level of 11µM/L after 3 weeks of infusion. However 
only 2% of the infused purified plasma AT drug reaches to the lung and therefore 
administration via aerosol has also been assessed (Wencker et al., 1998; Hubbard et al., 1989; 
Smith et al., 1989). Some positive effects of augmentation therapy have been observed in 
those with moderately impaired lung function (FEV1 30-65%) (Alpha-1-antitrypsin-
Deficiency-Study-Group, 1998; Abusriwil and Stockley, 2006), and some studies have also 
demonstrated that the treatment reduces airway LTB4, which plays important role in 
exacerbations (Stockley et al., 2002). However, the therapeutic effect of augmentation 
therapy is debated due to the lack of a randomized controlled clinical trial (Burrows, 1983; 
Wewers and Gadek, 1987). There are however problems with conducting such studies: in 
particular the large numbers of patients with this rare disease required for placebo-
controlled and randomized clinical trials; the length of follow-up required to assess efficacy 
and the limited supply and cost of the treatment (Abusriwil and Stockley, 2006).  
 
Drug Manufacturer Method of 
preparation 
(viral 
inactivation) 
Minimum specific 
functional 
inhibitor activity 
per mg total 
protein
Countries approved for 
use 
Prolastin® Talecris 
Biotherapeutics, 
Research Traingle 
Park, NC 
Pasteurization ≥ 0.35 mg Argentina, Austria, 
Bahamas, Barbados, 
Belgium, Bermuda, 
Canada, Denmark, 
Finland, Germany, 
Greece, Guam, Ireland, 
Italy, Netherlands, 
Norway, Oman, 
Poland, Portugal, 
Puerto Rico, Qatar, 
Spain, Sweden, 
Switzerland, US 
ZemairaTM CSL Behring, 
King of Prussia, 
PA
Pasteurization ≥ 0.7 mg US 
AralastTM 
(which was 
initially 
called 
Respitin) 
Baxter, Deerfield, 
IL 
Solvent 
detergent and 
nanofiltration 
≥ 0.55 mg US 
Trypsone® Grifols, SA. Solvent 
detergent and 
nanofiltration
≥ 0.7 mg Argentina, Brazil, 
Chile, Mexico, Spain, 
Table 2. Preparations of purified human plasma antitrypsin are available world wide 
Modrykamien and Stoller, 2009; Stockley et al., 2010; Louie et al., 2005; Barker et al., 1997. 
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A recent study analyzed results from two randomized, double-blind, placebo-controlled 
trials to date; a 2-center Danish-Dutch study (n = 54) and the 3-center EXAcerbations and CT 
scan as Lung Endpoints (EXACTLE) study (n = 65) (Stockley et al., 2010). The study 
investigated the efficacy of IV AT augmentation therapy on emphysema progression using 
CT densitometry over an average mean follow-up of about 2.5 years. The study confirmed 
that IV augmentation therapy significantly reduces the decline in lung density. Decline from 
baseline to last CT scan was -4.082 g/L versus -6.379 g/L for placebo, with the treatment 
difference of 2.297 (95% CI, 0.669 to 3.926; p=0.006), the corresponding annual declines were 
-1.73 and -2.74 g/L/yr, respectively) and may therefore reduce the future risk of mortality in 
patients with AT deficiency related emphysema, in favour of IV AT augmentation therapy. 
There is no evidence that IV augmentation therapy with purified plasma AT preparations is 
effective in MZ genotypes. MZ patients are at risk for accelerated airflow obstruction/lung 
disease as mentioned above and that augmentation therapy in MZ patients can be 
associated with side effects (Stoller et al., 2003/2009). The Medical and Scientific Advisory 
Committee of the Alpha-1 Foundation (Sandhaus et al., 2008) concluded that augmentation 
therapy for MZ phenotypes should be avoided. 
4.2 Alpha-1 antitrypsin deficiency and Lung volume reduction surgery 
Recently lung volume reduction surgery (LVRS) has been proposed as a treatment for 
severe emphysema. Over the years studies reported both in favour and against LVRS in AT 
deficient patients (Dauriat et al., 2006; Tutic et al., 2004). Because LVRS offers only short-
term benefits for most AT deficient patients LVRS should not be recommended in these 
patients pending additional studies (ATS–ERS, 2003). This data is further supported by 
landmark studies from the National Emphysema Treatment Trial (NETT) (Fishman et al 
2003; Stoller et al 2007) that included 1218 randomized subjects and 10 who were 
randomized had severe Z-AT deficiency and underwent LVRS. Deficient individuals had a 
shorter duration in FEV1 rise, smaller increase in exercise capacity at 6 months, and higher 
mortality (20% vs. 0% compared with medical treatment) after 2 years. Although these 
conclusions are inherently limited by the small number of patients analyzed, LVRS cannot 
clearly be recommended for this population based on the above data (Stoller et al 2007). In 
addition, most patients with Z-AT deficiency have lower lobe predominant emphysema, 
which showed the least surgical benefit in NETT (leading to worse outcomes in good 
exercise capacity patients) (Stoller et al 2007). Although LVRS has small functional gains and 
a shorter-lasting effect in AT deficient patients than in patients with normal AT emphysema, 
it could potentially serve as a bridging procedure that postpones the need for lung 
transplantation (Dauriat et al., 2006; Tutic et al., 2004). Emerging techniques for 
bronchoscopic lung volume reduction are covered in another chapter. 
4.3 Alpha-1 antitrypsin deficiency and Lung transplantation  
End stage pulmonary emphysema is the most common indication for lung transplantation 
worldwide. Lung transplantation is considered in patients with declining lung function or 
symptomatic patients with a poor quality of life after receiving all conservative treatment 
options including smoking cessation and rehabilitation programmes. A functional 
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improvement and better quality of life are clear benefits deriving from lung transplantation, 
while a survival advantage has not yet been proven (Marulli and Rea, 2008). Studies have 
shown advantage of single versus double lung transplantation for COPD or AT deficiency. 
However, a common cause of death PiZ post transplantation was due to pulmonary 
infection and bronchiolitis obliterans syndrome (BOS), and sepsis in the presence of excess 
NE (Meyer et al., 2001; Tanash et al., 2011; de Perrot et al., 2004). A recent study analyzed a 
total of 83 PiZZ patients with severe emphysema who underwent lung transplantation 
between 1990 and June 2010 compared to 70 age, gender, smoking history and lung function 
matched controls (Tanash et al., 2011). Of 83 transplanted patients, 62 (75%) underwent 
single-lung transplantation. During follow-up, 37 (45%) deaths occurred in transplanted 
patients and 45 (64%) in the non transplanted patients. In the transplanted patients, the 
estimated median survival time was 11 years (95% confidence interval [CI] 9 to 14 years), 
compared with 8 years (95% CI 4 to 6 years) for the non transplanted patients (p = 0.006) 
(Tanash et al., 2011). Constant annual death rates due to BOS and other complications result 
in a 50% 5-year survival (Patterson and Cooper, 1995). In addition, Mal and colleagues (Mal 
et al., 2004) have shown an association between cigarette smoking induced NE activity and 
recurrence of pulmonary emphysema in the transplanted lung of a 49 year old PiZ patient 
11 years after receiving single lung transplant. Therefore, lung transplantation should only 
be offered to selected candidates.  
4.4 Treatment of Z α1-antitrypsin-associated liver disease 
A major distinction between pathogenesis of lung and liver disease in Z-AT deficiency is 
loss of function and gain of function, respectively. In liver disease it relates to the 
intracellular accumulation of misfolded and unsecreted AT from hepatocytes rather than 
unopposed elastolysis in the lung due to lack of AT. Therefore, augmentation therapy does 
not confer protect against and not indicated for liver disease relating to severe AT 
deficiency. Other strategies have been assessed for treatment of Z-AT related liver disease 
including targeting a lateral hydrophobic cavity to prevent polymerization, and enhancing 
clearance of Z-AT aggregates by drugs promoting autophagy (Zhou et al., 2004; Burrows et 
al., 2000; Mallya et al., 2007; Hedvegi et al., 2010; Devlin et al., 2001; Kaushal et al., 2010). 
These methods reduce intracellular aggregation of Z-AT but do not increase the secretion Z-
AT. Use of short synthetic peptides targeting ǃ-sheet A may show therapeutic potential for 
Z-AT related liver and lung disease (Figure 3) (Chang et al., 2006; 2009; Alam et al., 
Unpublished observation).  
5. Novel treatments in development 
5.1 Gene therapy 
Future therapies for ǂ1-antitrypsin deficiency include gene therapy. Supplementing AT by 
gene delivery is an alternative way to increase the local AT in lung. Preclinical studies 
have shown that the Adeno-associated viral vector is capable in increasing the AT 
concentration to over 11μM in the lung. The safety and efficiency of this approach is 
under evaluation (Flotte, 2002; Flotte et al., 2004; Stecenko and Brigham, 2003; Flotte and 
Mueller, 2011).  
www.intechopen.com
 
Emphysema 
 
62
Peptide
A. Polymer inhibition by 12 mer peptide
B. Polymer inhibition by targeting ǃ-sheet A 
+12 mer
peptide
 
A. Z mutation (E342K) perturbs the structure of AT to allow opening of ǃ-sheet A, which then accepts 
the RCL of another molecule to form a dimer (left) that can extend to form chains of polymers as 
depicted in Fig. 1. 12-mer peptide can anneal to ǃ-sheet A thereby preventing polymer formation (right). 
B. Z mutation allows partial insertion of the RCL. This opens the lower part of ǃ-sheet A thereby 
favouring polymerization (left). Understanding the configuration of the reactive loop and interacting 
with ǃ-sheet A prompted the hypothesis that a 6-mer with homology to P7-2 of the RCL would 
specifically bind to Z-AT and so prevent polymerization and explained why the 12-mer peptide 
preferentially bound to M-AT (right). Reproduced and adapted from Lomas and Mahadeva, 2002; 
Mahadeva et al., 2002; Chang et al., 2009.  
Fig. 3. Representation Z ǂ1-antitrypsin polymerization and the design of a selective 
inhibitor. 
6. Summary 
Alpha-1-antitrypsin is the most important proteinase inhibitor in maintaining the 
proteinase/antiproteinase balance within the lung. The recognition of the association 
between plasma deficiency of ǂ1-antitrypsin and emphysema over 40 years ago has led to 
the proteinase-antiproteinase hypothesis of lung disease which remains central to 
understanding lung biology. In the last 20 years there has been significant progress in our 
understanding of ǂ1-antitrypsin. Alpha-1 antitrypsin may modulate other biological 
processes such as apoptosis and inflammatory cell recruitment. Z ǂ1-antitrypsin 
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polymerizes within the liver and this accounts for its severe plasma deficiency, and ǂ1-
antitrypsin polymers may have a role in the progression of emphysema, but this requires 
further investigation. Recent and ongoing studies should clarify the role of augmentation 
therapy and lung volume reduction in subgroups of PiZZ homozygotes, and the 
understanding of polymer formation has raised the exciting prospect of developing new 
therapeutic strategies for the liver and lung disease associated with Z ǂ1-antitrypsin. 
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